HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 63 people enrolled
- Started
- 16 May 2019
- Ended
- 29 Dec 2023
- Type of study
- Observational, 4 groups
- Treatments tested
- Neuropsychological assessment
- Neuroimaging
- Record updated
- 27 March 2025
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Adult Veteran (>21 years)
- Able to provide informed consent
Who cannot take part
- Contraindications to MRI (such as surgical aneurysm clips, pacemaker, prosthetic heart valve, neuro-stimulator, implanted pumps, cochlear implants, metal rods, plates or screws, previous surgery, hearing aids, history of welding, metal shrapnel)
- Current substance use disorder other than alcohol (except nicotine or caffeine)
- Medical conditions likely to impact immunological function or central nervous system function (such as HIV, cancer, lupus, stroke, neurodegenerative disease, hepatic encephalopathy, multiple sclerosis, or a traumatic brain injury)
- Past or present schizophrenia, schizoaffective disorder, or current psychosis or mania
- Visible intoxication or impaired capacity to understand study risks and benefits or otherwise provide informed consent
- Visual or auditory impairments that would prevent valid neuropsychiatric testing
Where in United States
- VA Portland Health Care System, Portland, ORPortland, United States
About the trial
What the trial wants to find out
The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and after direct-acting antiviral (DAA) therapy [a new treatment for chronic infection with the hepatitis C virus (HCV)]. Demographically-matched comparison groups of Veterans without HCV (HCV-, with and without AUD) will similarly be evaluated to determine the relative contribution of HCV and an HCV "cure" to outcomes putatively affected by alcohol abuse.
Read full original descriptionShow less
Two specific aims are proposed.
Aim 1: Determine the impact of DAA therapy and a sustained viral response on central nervous system (CNS) function.
Aim 2: Evaluate the effects of AUD and unhealthy alcohol drinking on DAA therapy outcomes and CNS function.
The information learned will address a critical gap in knowledge concerning the effects of alcohol use on DAA therapy outcomes and will help inform treatment guidelines that could be translated to clinical practice, such as targeted interventions to treat AUD in conjunction with HCV infection and follow-up strategies for patients who successfully complete DAA therapy but then need care for other potential CNS-related outcomes.
The 4 groups in the trial
- AUD+/HCV+
* With current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV
Treatment: Neuropsychological assessment and Neuroimaging
- AUD-/HCV+
* Without current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV
Treatment: Neuropsychological assessment and Neuroimaging
- AUD+/HCV-
-With Alcohol Use Disorder and without HCV
Treatment: Neuropsychological assessment and Neuroimaging
- AUD-/HCV-
-Without Alcohol Use Disorder and without HCV
Treatment: Neuropsychological assessment and Neuroimaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 March 2025